<DOC>
	<DOCNO>NCT02737657</DOCNO>
	<brief_summary>The primary purpose study describe tolerability canagliflozin sulphonylurea ( administer metformin without DPP-4 inhibitor ) , term percentage patient least one episode hypoglycaemia , patient T2DM fast Ramadan .</brief_summary>
	<brief_title>An Observational Study Evaluate Tolerability Canagliflozin Sulphonylurea Type 2 Diabetes Patients During Ramadan</brief_title>
	<detailed_description>This non-randomized , parallel-cohort , prospective , multicenter ( one hospital work medical research study ) , observational study describe treatment T2DM canagliflozin Holy Month Ramadan . Observed participant participant T2DM ( time enrollment ) treat either canagliflozin sulphonylurea , administer background therapy metformin without DPP-4 inhibitor within clinical practice , intend fast Ramadan period . On enrollment , patient enter one two parallel treatment cohort base ongoing T2DM therapy : canagliflozin metformin without DPP-4 inhibitor treatment interest , sulphonylurea metformin without DPP-4 inhibitor serve reference standard treatment . Safety monitor throughout study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Participants confirm diagnosis type 2 diabetes 12 month enrollment Participants treat canagliflozin sulphonylurea , background therapy metformin without dipeptidyl peptidase 4 ( DPP4 ) inhibitor , &gt; 12 week enrollment Participants Intends fast Ramadan 2016 Participants Will able continue product study ( i.e. , canagliflozin sulphonylurea , metformin without DPP4 inhibitor ) Ramadan period , judge participate physician Participants glycated hemoglobin ( HbA1c ) measurement less equal ( &lt; = ) 8.5 % within 8 week start Ramadan . Participant treat insulin and/or type 2 diabetes mellitus ( T2DM ) therapy canagliflozin , sulphonylurea , metformin without DPP 4 inhibitor , change T2DM therapy within 12 week enrollment ( dose change canagliflozin , sulphonylurea , metformin , DPP 4 inhibitor applicable accept ) Participant currently treat loop diuretic Participants history severe hypoglycaemia event within 6 month prior enrollment ( define hypoglycaemia event patient require assistance another person , result seizure loss consciousness ) . Participants heart failure ( NYHA 34 ) advance cardiovascular disease . Participants estimate glomerular filtration rate ( eGFR ) less ( &lt; ) 60 milliliter/minute ( mL/min ) /1.73 m^2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Metformin</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>INVOKANA</keyword>
	<keyword>Sulfonylurea</keyword>
</DOC>